So, after researching for a short bit into the CT Order recently posted. this is what I have seen so far from the 2013 Full Year 10K as well as the 2014 Q1 Earnings Report pertaining to the "Exhibit #'s" that were listed in the recent SEC/CTO form, as noted below:
Exhibit 2.1 through March 17, 2019:
Unit Purchase Agreement, dated as of January 12, 2014, between Galena Biopharma, Inc. and Mills Pharmaceuticals, LLC.+**
* this "Exhibit" was noted on both the Full Year 2013 and Q1 2014 Earning Reports
Exhibit 10.36 through January 13, 2024:
License and Development Agreement, dated January 13, 2014, between Galena Biopharma, Inc. and Dr. Reddy’s Laboratories, Ltd.+**
Exhibit 10.37 through December 20, 2016:
Exclusive License Agreement, dated as of December 20, 2013, between Mills Pharmaceuticals, LLC and BioVascular, Inc.+**
Any thoughts on if this is anything for the "positive" for us, or is it just "standard practice"?
Market Data 
Markets 
AI
